The taught MSc in Regenerative Medicine at NUI Galway graduated its one-hundredth student recently. This course focuses on stem cells, gene therapy and tissue engineering, focusing on how they can be applied to develop new therapeutics.
The course is the only one of its kind in Ireland. Students who have completed this course have gone to work in pharmaceutical and biomedical companies in Ireland and abroad. Many graduates have chosen to follow research-based careers in this dynamic field and are pursuing PhDs in countries all over the world (Ireland, the UK, Spain, the Netherlands, Austria and America). Regenerative Medicine is an exciting emerging discipline, which aims to develop novel therapeutics to repair and regenerate damaged and diseased organs. These therapeutics utilize stem cells, gene therapy, biomaterials, engineered tissue and biologically active compounds. This 12-month taught MSc course will equip you with the skills to participate in this discipline. Modules will address the science behind Regenerative Medicine as well as its application to human disease.
What you need to know
Where is the course located?
What is the length of the course?
12 Months (1 Year) Full-time
When can I apply?
You can apply today
When does the course start?
Application Closing Date
Open for an application
Number of Places
Fees and Funding
Non-EU Tuition Fees
Living Costs per year
Features and Benefits
- Graduates of this course have found employment in biomedical device amd biotechnology companies and clinical research organisations in Ireland and abroad.
- Many graduates have obtained PhD studentships in Ireland and the UK, as well as in Austria, Germany, Spain, the Netherlands, Canada and the USA. Some graduates have gone on to study medicine, and graduates with clinical backgrounds have progressed to clinical fellowships.
How to Apply
Once you are ready to start your application, please click on APPLY NOW
As part of your application, you will be required to submit:
- Your academic history and transcripts (Actual and/or Predicted Grades)
- Proof of English proficiency (typically IELTS or TOEFL scores)
- 2 letters of recommendation
- A copy of your passport
- Personal Statement
- Extra requests for certain courses
Minimum entry requirements
Applicants should have, or should expect to obtain, at least a Second Class Honors degree in a biological / life science or medicine. Students who have a degree without Honors in a related area and have three or more years of practical experience in the subject area will also be eligible to apply for this course.
Medicine (No less than 6.5 in any Component)
[This requirement applies to incoming first year students only]
IELTS: 6.5 Overall
Pearson (PTE): 61
Duolingo English Test (DET)**: 110
• Temporary measure for 2020 only in response to COVID-19
Special Entry Requirements
Graduates of this course have found employment in biomedical device and biotechnology companies and clinical research organisations in Ireland and abroad. Many graduates have obtained PhD studentships in Ireland and the UK, as well as in Austria, Germany, Spain, the Netherlands, Canada and the USA. Some graduates have gone on to study medicine, and graduates with clinical backgrounds have progressed to clinical fellowships.
Special features: As part of this MSc course, students will undertake a summer-long, laboratory-based research project. In previous years, these projects have been based at NUI Galway, Galway University Hospital, and in research groups based in Dublin and Maynooth. The MSc is administered by the Regenerative Medicine Institute (REMEDI), a world-class biomedical research institute recognized as Ireland’s primary center for stem cell and gene therapy research, and a world leader in the field of regenerative medicine. REMEDI’s main focus is to use cells and genes to regenerate healthy tissues that can be used to repair or replace other tissues and organs with a minimally invasive approach.
REMEDI is home to Ireland’s only stem cell manufacturing facility, CCMI, the Center for Cell Manufacturing Ireland. This state-of-the art facility will translate, as well as manufacture, research from REMEDI’s programmes into cell-based medicinal products for clinical trials.